Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy
Alexander C. Cohen, B.M. Roane, Charles A. Leath
Drugs (2020) Vol. 80, Iss. 3, pp. 217-227
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Biological and clinical aspects of HPV-related cancers
Klaudia Szymonowicz, Junjie Chen
Cancer Biology and Medicine (2020) Vol. 17, Iss. 4, pp. 864-878
Open Access | Times Cited: 281
Recurrent or primary metastatic cervical cancer: current and future treatments
Christine Gennigens, Guy Jérusalem, L. Lapaille, et al.
ESMO Open (2022) Vol. 7, Iss. 5, pp. 100579-100579
Open Access | Times Cited: 81
A novel electrospun nanofiber system with PEGylated paclitaxel nanocrystals enhancing the transmucus permeability and in situ retention for an efficient cervicovaginal cancer therapy
Huan Duan, Haini Chen, Chenrui Qi, et al.
International Journal of Pharmaceutics (2023) Vol. 650, pp. 123660-123660
Closed Access | Times Cited: 45
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature
Ottavia D’Oria, Giorgio Bogani, Ilaria Cuccu, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 25, Iss. 1, pp. 55-65
Closed Access | Times Cited: 29
Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions
Jiatian Ye, Lan Zheng, Yuedong He, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 23
Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer
Chenying Liu, Xiaolong Qian, Chunyan Yu, et al.
Cancer Letters (2024) Vol. 586, pp. 216642-216642
Closed Access | Times Cited: 9
Green Biosynthesized Silver Nanoparticles With Aqueous Extracts of Ginkgo Biloba Induce Apoptosis via Mitochondrial Pathway in Cervical Cancer Cells
Zhen Xu, Feng Qi, Min Wang, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 61
Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer
Huan-he Ni, Lin Zhang, He Huang, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 53
Optimal treatment in locally advanced cervical cancer
Christine Gennigens, Marjolein De Cuypere, Johanne Hermesse, et al.
Expert Review of Anticancer Therapy (2021) Vol. 21, Iss. 6, pp. 657-671
Open Access | Times Cited: 47
Human Papillomavirus: Challenges and Opportunities for the Control of Cervical Cancer
Patricia Piña‐Sánchez
Archives of Medical Research (2022) Vol. 53, Iss. 8, pp. 753-769
Open Access | Times Cited: 32
Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics
Archana Adhikari, Syed Mohammed Basheeruddin Asdaq, Maitham A. Al Hawaj, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 970-970
Open Access | Times Cited: 37
The interplay between the vaginal microbiome and innate immunity in the focus of predictive, preventive, and personalized medical approach to combat HPV-induced cervical cancer
Erik Kúdela, Alena Líšková, Marek Samec, et al.
The EPMA Journal (2021) Vol. 12, Iss. 2, pp. 199-220
Open Access | Times Cited: 33
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions
Chunxue Zhang, Yaru Sheng, Xiao Sun, et al.
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 3, pp. 891-925
Open Access | Times Cited: 13
Exosomal NOX1 promotes tumor-associated macrophage M2 polarization-mediated cancer progression by stimulating ROS production in cervical cancer: a preliminary study
Liying Gu, Chunyang Feng, Meng Li, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 13
Long non-coding RNAs as critical regulators and novel targets in cervical cancer: current status and future perspectives
Shalu Ranga, Ritu Yadav, Ravindresh Chhabra, et al.
APOPTOSIS (2023) Vol. 28, Iss. 7-8, pp. 925-942
Open Access | Times Cited: 11
Tannic acid chitosan iron oxide nanocomposite for cervical cancer treatment
Farahnaz Barahuie, Dena Dorniani, Bullo Saifullah, et al.
Inorganic Chemistry Communications (2024) Vol. 162, pp. 112160-112160
Closed Access | Times Cited: 4
Immunotherapy in cervical cancer: An evolutionary paradigm in women's reproductive health
Mansi Damani, Akshada Mhaske, Sayali Dighe, et al.
Critical Reviews in Therapeutic Drug Carrier Systems (2025) Vol. 42, Iss. 3, pp. 55-88
Closed Access
Targeted demethylation of the EphA7 promoter inhibits tumorigenesis via the SP1/DNMT1 and PI3K/AKT axes and improves the response to multiple therapies in cervical cancer
Wenfan Zhang, Jing Zhao, Xueting Fan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
RaPiDS (GOG-3028): Randomized Phase II Study of Balstilimab Alone or in Combination with Zalifrelimab in Cervical Cancer
David M. O’Malley, Leslie M. Randall, Camille Gunderson Jackson, et al.
Future Oncology (2021) Vol. 17, Iss. 26, pp. 3433-3443
Open Access | Times Cited: 24
Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer
Chinmoy K Bose
Medical Oncology (2022) Vol. 39, Iss. 4
Closed Access | Times Cited: 16
MiR-136-5p in cancer: Roles, mechanisms, and chemotherapy resistance
Manlin Zhang, Tongtong Xu, Deming Tong, et al.
Gene (2024) Vol. 909, pp. 148265-148265
Closed Access | Times Cited: 3
PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer
Xiaoyu Ji, Lei Sui, Kejuan Song, et al.
Cancer Medicine (2021) Vol. 10, Iss. 14, pp. 4743-4751
Open Access | Times Cited: 21
New light on treatment of cervical cancer: Chinese medicine monomers can be effective for cervical cancer by inhibiting the PI3K/Akt signaling pathway
Fangyuan Liu, Jiayue Xu, Rui Yang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 157, pp. 114084-114084
Open Access | Times Cited: 16
Circular RNA ARHGAP5 inhibits cisplatin resistance in cervical squamous cell carcinoma by interacting with AUF1
Sisi Deng, Lili Qian, Luwen Liu, et al.
Cancer Science (2023) Vol. 114, Iss. 4, pp. 1582-1595
Open Access | Times Cited: 9
Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities
Congwang Zhang, Wuxuan Mei, Changchun Zeng
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188707-188707
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top